Focus Antitrust - 27 January 2021
In The News
CMA closes part of investigation into supply of anti-nausea tablets
The CMA has decided to close part of its investigation into the supply of anti-nausea tablets on administrative priorities grounds. The part relates to whether alleged separate agreements between each of (1) Alliance Pharmaceuticals and Focus and (2) Focus, Lexon and Medreich in relation to the supply of prochlorperazine 3mg buccal tablets in the UK in themselves individually broke competition law. The CMA is continuing its investigation of whether there was an alleged overarching agreement between the parties. Click here.
CAT orders remittal of FNZ / GBST merger inquiry
The Competition Appeal Tribunal has ordered the remittal of the FNZ / GBST merger inquiry following the CMA’s request. The CMA had identified errors in its findings following an appeal by the parties to the merger. Click here.
UK
CMA
- The CMA has published its issues statement as part of its Liberty Global plc / Telefónica S.A. merger inquiry. Click here.
For more information please contact Paul Stone.
